Mirum hepatitis drug lowers virus levels in late-stage study
Brelovitug met the main goal in chronic hepatitis delta virus patients, with 56% and 45% response rates versus 0% in delayed treatment at 24 weeks.
Sept 28 (Reuters) — Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study. Here are some key details: Mirum was testing brelovitug, an experimental monoclonal antibody that binds to the hepatitis B surface antigen, a protein found on the surface of the virus The company was testing the treatment for chronic hepatitis delta virus, a liver infection that affects only people already infected with hepatitis B The disease can cause severe symptoms that can lead to liver damage and even death.
It affects about 230,000 people in the US and Europe, the company estimates At 24 weeks, 56% of patients who were given 300 milligrams of brelovitug and 45% of patients who were given 900 milligrams achieved a reduction of the hepatitis D virus and normal liver enzyme levels, compared with 0% in the delayed treatment group, the company said. Treatment with brelovitug was well tolerated across dose groups, with a safety profile consistent with previously reported data, Mirum said. Full results from the study will be presented at an upcoming medical congress, with the company expecting to submit a marketing application for the drug to the US FDA in the first half of 2027.
com;)